Download pdf
Research Progress on the Role of Immune Checkpoint Inhibitors in Liver Cancer Therapy
- 1 College of Life Science, Northeast Forestry University, Harbin, China
* Author to whom correspondence should be addressed.
Abstract
Globally, hepatocellular carcinoma (HCC) is the third most common cause of cancer-related mortality and the sixth most common type of cancer, with pronounced therapeutic challenges in the Asia-Pacific region. Its progression is driven by an immunosuppressive tumor microenvironment (TME) linked to hepatitis B and C viruses (HBV/HCV) or metabolic-associated steatohepatitis (MASH).Immune checkpoint inhibitors (ICIs) are a breakthrough treatment for advanced HCC because they reverse T-cell exhaustion by targeting the PD-1/PD-L1 or CTLA-4 pathways. However, single-agent ICIs yield modest efficacy in second-line therapy (15-20% objective response rate [ORR], 12-15 months median overall survival [OS]), limited by TME-mediated immune evasion.Combination therapies now dominate clinical strategies: (1) Immune-targeted regimens (e.g., anti-angiogenics + ICIs) enhance TME immune infiltration, extending median OS to 19.2 months; (2) Dual checkpoint blockade (such as PD-1 + CTLA-4 inhibitors) boosts ORR to 36%, albeit requiring careful management of immune-related toxicities; (3) Immune-local therapy integration (e.g., ablation/radiation + ICIs) leverages antigen release to amplify systemic responses, achieving 90% disease control rates.Despite these advances, persistent hurdles include TME heterogeneity, drug resistance, and region-specific etiologies (e.g., HBV dominance in Asia). Future progress hinges on multi-omics profiling to decipher molecular drivers, development of predictive biomarkers, and personalized immunomodulatory approaches tailored to individual TME landscapes and etiological factors. Addressing these challenges may unlock more durable responses in this heterogeneous malignancy.
Keywords
immune checkpoint, liver cancer, gene expression, immune regulation
[1]. Xu, F., Jin, T., Zhu, Y. and Dai, C. (2018) Immune checkpoint therapy in liver cancer. Journal of Experimental & Clinical Cancer Research, 37, 1-12.
[2]. Liu, X. and Qin, S. (2019) Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges. The Oncologist, 24, S3–S10.
[3]. Llovet, J.M., Castet, F., Heikenwalder, M., Maini, M.K., Mazzaferro, V., Pinato, D.J., Pikarsky, E., Zhu, A.X. and Finn,R.S.(2022) Immunotherapies for hepatocellular carcinoma.Nature Reviews Clinical Oncology,19,151-172.
[4]. Chen, Y., Hu, H., Yuan, X., Fan, X.and Zhang, C. (2022) Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma. Frontiers in Immunology, 13, 896752.
[5]. Ruff, S.M., Manne, A., Cloyd, J.M., Dillhoff, M., Ejaz, A.and Pawlik, T.M. (2023) Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Current Oncology, 30, 5863-5875.
[6]. Machairas, N., Tsilimigras, D.I. and Pawlik, T.M. (2022) Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Cancers,14, 2018.
[7]. Naimi, A., Mohammed, R.N., Raji, A., Chupradit, S., Yumashev, A.V., Suksatan, W., Shalaby, M.N., Thangavelu, L., Kamrava, S., Shomali, N., Sohrabi, A.D., Adili, A., Noroozi-Aghideh, A. and Razeghian, E. (2022) Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Communication and Signaling, 20, 44.
[8]. Yoo, M.J., Long, B., Brady, W.J., Holian, A., Sudhir, A. and Gottlieb, M. (2021) Immune checkpoint inhibitors: An emergency medicine focused review. The American Journal of Emergency Medicine,50,335-344.
[9]. Arafat Hossain, M. (2024) A comprehensive review of immune checkpoint inhibitors for cancer treatment. International Immunopharmacology,143,113365.
[10]. Li, N., Hou, X., Huang, S., Tai, R., Lei, L., Li, S., Abuliz, A., Wang, G. and Yang, S. (2022) Biomarkers related to immune checkpoint inhibitors therapy. Biomedicine & Pharmacotherapy, 147, 112470.
Cite this article
Gong,Z. (2025). Research Progress on the Role of Immune Checkpoint Inhibitors in Liver Cancer Therapy. Theoretical and Natural Science,93,26-31.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 3rd International Conference on Environmental Geoscience and Earth Ecology
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).